Inventor · disambiguated record
Robert James Peach
Also filed as: PEACH ROBERT · PEACH ROBERT J · PEACH ROBERT JAMES
41 granted patents·22 pending applications·1,151 citations·filing 1994–2024
98Inventor score
Top patents by PatentIndex Score
63 records- 0197US7358354B2Polynucleotides encoding BSL3BRISTOL MYERS SQUIBB CO·Filed 2006·Granted Apr 15, 2008·75 cites·24 claims
- 0297US7094874B2Soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Aug 22, 2006·86 cites·42 claims
- 0397US6965018B2Antibodies directed to B7-related polypeptide, BSL-2BRISTOL MYERS SQUIBB CO·Filed 2001·Granted Nov 15, 2005·135 cites·28 claims
- 0496US7368554B2Polynucleotides encoding BSL2v1c2-IgBRISTOL MYERS SQUIBB CO·Filed 2006·Granted May 6, 2008·53 cites·11 claims
- 0596US7279567B2Polynucleotides-encoding B7-related polypeptide, BSL2-L165-35BBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Oct 9, 2007·77 cites·16 claims
- 0696US5773253AMYPPPY variants of CTL A4 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Jun 30, 1998·172 cites·17 claims
- 0795US7723479B2BSL3 polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted May 25, 2010·36 cites·16 claims
- 0895US7304033B2Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Dec 4, 2007·90 cites·32 claims
- 0995US6090914ACTLA4/CD28Ig hybrid fusion proteins and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Jul 18, 2000·149 cites·7 claims
- 1094US7105166B1Soluble CTLA4 mutant molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Sep 12, 2006·33 cites·12 claims
- 1193US8354513B2Polynucleotides encoding BSL2vcvc-lgBRISTOL MYERS SQUIBB CO·Filed 2010·Granted Jan 15, 2013·10 cites·16 claims
- 1293US7700556B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Apr 20, 2010·14 cites·8 claims
- 1392US9409970B2Polynucleotides encoding BSL2v2c2BRISTOL MYERS SQUIBB CO·Filed 2014·Granted Aug 9, 2016·14 cites·5 claims
- 1492US8497247B2Methods for treating type I diabetes mellitus by administering a soluble CTLA4 moleculeCOHEN ROBERT·Filed 2012·Granted Jul 30, 2013·15 cites·8 claims
- 1592US7455835B2Methods for treating immune system diseases using a soluble CTLA4 moleculeBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Nov 25, 2008·57 cites·31 claims
- 1690US7829534B2Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Nov 9, 2010·16 cites·14 claims
- 1790US7439230B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Oct 21, 2008·22 cites·16 claims
- 1889US9758565B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Sep 12, 2017·6 cites·14 claims
- 1989US9388147B2Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesisRECEPTOS INC·Filed 2015·Granted Jul 12, 2016·9 cites·36 claims
- 2089US8722632B2Methods for treating Sjogrens syndrome by administering a soluble CTLA4 moleculeBRISTOL MYERS SQUIBB CO·Filed 2013·Granted May 13, 2014·9 cites·8 claims
- 2189US8227420B2Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAIDCOHEN ROBERT·Filed 2010·Granted Jul 24, 2012·10 cites·34 claims
- 2289US8148332B2Method for treating a rheumatic disease using a soluble TLA4 moleculeCOHEN ROBERT·Filed 2011·Granted Apr 3, 2012·9 cites·8 claims
- 2388US9296808B2Methods for treating scleroderma by administering a soluble CTLA4 moleculeBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Mar 29, 2016·7 cites·1 claims
- 2488US8703718B2Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 moleculeBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Apr 22, 2014·7 cites·8 claims
- 2588US8362048B2Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesisRECEPTOS INC·Filed 2010·Granted Jan 29, 2013·10 cites·24 claims
- 2688US7807786B2BSL2v1c2 polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Oct 5, 2010·5 cites·13 claims
- 2787US8674076B2BSL2vcvc-lg polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Mar 18, 2014·3 cites·14 claims
- 2885US8080636B2BSL3 antibodiesMIKESELL GLEN EUGENE·Filed 2010·Granted Dec 20, 2011·7 cites·24 claims
- 2984US8785398B2Methods of treatment using CTLA4 mutant moleculesPEACH ROBERT JAMES·Filed 2011·Granted Jul 22, 2014·6 cites·11 claims
- 3082US11390669B2Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodiesABBVIE INC·Filed 2017·Granted Jul 19, 2022·2 cites·27 claims
- 3182US10052360B2Methods for treating dermatomyositis or polymyositis by administering a soluble CTLA4 moleculeBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Aug 21, 2018·2 cites·16 claims
- 3282US2024425582A1Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodiesABBVIE INC·Filed 2024·Application pending·0 cites
- 3380US12129294B2Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodiesABBVIE INC·Filed 2023·Granted Oct 29, 2024·0 cites·15 claims
- 3480US10239846B2Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesisCELGENE INT II SARL·Filed 2017·Granted Mar 26, 2019·2 cites·10 claims
- 3580US8664360B2BSL3 polypeptidesMIKESELL GLEN EUGENE·Filed 2011·Granted Mar 4, 2014·3 cites·4 claims
- 3677US12122826B2Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodiesABBVIE INC·Filed 2022·Granted Oct 22, 2024·0 cites·27 claims
- 3777US2021115107A1Methods of treatment using ctla4 moleculesBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 3874US10590183B2BSL2v2c2-Ig polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 17, 2020·0 cites·2 claims
- 3973US2020369744A1BSL2v2c2-Ig POLYPEPTIDESBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 4070US2019185538A1Methods of treatment using ctla4 moleculesBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 4169US9399052B2Polynucleotides encoding BSL2v2c2-IgBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jul 26, 2016·0 cites·25 claims
- 4269US2020079835A1B7-related nucleic acids and polypeptides useful for immunomodulationBRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
- 4368US10370428B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Aug 6, 2019·0 cites·10 claims
- 4466US10308702B2BSL2v2c2-Ig polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 4, 2019·0 cites·19 claims
- 4564US10400023B2B7-related nucleic acids and polypeptides useful for immunomodulationBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Sep 3, 2019·0 cites·17 claims
- 4662US2015017677A1Cancer stem cellsECLIPSE THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 4761US2007071674A1Polynucleotides encoding novel isoforms of IGSF9MCLACHLAN KAREN·Filed 2006·Application pending·0 cites
- 4858US2004258616A1Compositions and methods for treating cancer using IGSF9 and LIV-1IDEC PHARMA CORP·Filed 2004·Application pending·0 cites
- 4958US2013244268A1Cancer stem cells expressing abcg2BIONOMICS INC·Filed 2013·Application pending·0 cites
- 5057US2013231326A1Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesisRECEPTOS INC·Filed 2013·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Robert James Peach files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →